Home
/
Aligos Therapeutics, Inc.
/
Financials
/
Quarterly
Aligos Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Aligos Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$741.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$965.0K
Aug 6, 2025
Q1
2025
Mar 31, 2025
$311.0K
May 6, 2025
Q3
2025
Sep 30, 2024
$1.25M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$1.06M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$694.0K
May 6, 2025
Q3
2024
Sep 30, 2023
$1.09M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$4.29M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$140.0K
May 7, 2024
Q3
2023
Sep 30, 2022
$0
Nov 2, 2023
Q2
2023
Jun 30, 2022
$0
Aug 3, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($31.54M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($15.86M)
Aug 6, 2025
Q3
2025
Jun 30, 2025
($15.86M)
Nov 6, 2025
Q3
2025
Mar 31, 2025
$43.09M
Nov 6, 2025
Q1
2025
Mar 31, 2025
$43.09M
May 6, 2025
Q2
2025
Mar 31, 2025
$43.09M
Aug 6, 2025
Q3
2025
Sep 30, 2024
($19.26M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
$5.06M
Aug 6, 2025
Q3
2025
Jun 30, 2024
$5.06M
Nov 6, 2025
Q3
2025
Mar 31, 2024
($34.86M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($34.86M)
May 6, 2025
Q2
2025
Mar 31, 2024
($34.86M)
Aug 6, 2025
Q3
2024
Sep 30, 2023
($18.04M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($18.79M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($22.96M)
May 7, 2024
Q3
2023
Sep 30, 2022
($18.62M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($19.92M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($35.62M)
May 4, 2023
Q3
2022
Sep 30, 2021
($33.12M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($29.82M)
Aug 4, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($28.36M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($18.57M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($19.24M)
May 6, 2025
Q3
2025
Sep 30, 2024
($20.13M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($26.41M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($22.05M)
May 6, 2025
Q3
2024
Sep 30, 2023
($19.07M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($19.14M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($23.92M)
May 7, 2024
Q3
2023
Sep 30, 2022
($18.95M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($20.39M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($35.56M)
May 4, 2023
Q3
2022
Sep 30, 2021
($33.07M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($29.57M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($27.74M)
May 4, 2022
Q3
2021
Sep 30, 2020
($21.56M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($21.27M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($20.72M)
May 10, 2021
Q3
2020
Sep 30, 2019
($14.50M)
Nov 25, 2020